|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Alexandre Merieux||Exec. Chairman||1,38M||N/D||1974|
|Mr. Pierre Boulud||Chief Exec. Officer||1,05M||N/D||1971|
|Mr. Frederic Beseme||Head of CSR||21,99k||N/D||1956|
|Mr. Guillaume Bouhours||Exec. VP of Purchasing and Information Systems & CFO||N/D||N/D||1976|
|Sylvain Morgeau||Investor Relations||N/D||N/D||N/D|
|Ms. Audrey Dauvet||Exec. VP of Legal Affairs & Integrity||N/D||N/D||1974|
|Ms. Valerie Leylde||Exec. VP of HR, Communications & CSR||N/D||N/D||N/D|
|Mr. François Lacoste||Exec. VP of R&D||N/D||N/D||N/D|
|Mr. Mark Miller||Exec. VP & Chief Medical Officer||N/D||N/D||N/D|
|Mr. Pierre Charbonnier||Exec. VP of Global Quality, Manufacturing & Supply Chain||N/D||N/D||N/D|
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
L'ISS Governance QualityScore di bioMérieux S.A. al 1 settembre 2023 è 8. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 10.